References

1. Gerhard-Herman, M.D.; Gornik, H.L.; Barrett, C.; Barshes, N.R.; Corriere, M.A.; Drachman, D.E.; Fleisher, L.A.; Fowkes, F.G.R.; Hamburg, N.M.; Kinlay, S.; et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: A report of the American college of cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017, 135, e726–e779.
2. Frank, U.; Nikol, S.; Belch, J.; Boc, V.; Brodmann, M.; Carpentier, P.H.; Chraim, A.; Canning, C.; Dimakakos, E.; Gottsäter, A.; et al. ESVM Guideline on peripheral arterial disease. Vasa Eur. J. Vasc. Med. 2019, 48, 1–79.
3. Fowkes, F.G.R.; Rudan, D.; Rudan, I.; Aboyans, V.; Denenberg, J.O.; McDermott, M.M.; Norman, P.E.; Sampson, U.K.; Williams, L.J.; Mensah, G.A.; et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet 2013, 382, 1329–1340.
4. Hajibandeh, S.; Hajibandeh, S.; Shah, S.; Child, E.; Antoniou, G.A.; Torella, F. Prognostic significance of ankle brachial pressure index: A systematic review and meta-analysis. Vascular 2017, 25, 208–224.
5. Jirak, P.; Mirna, M.; Wernly, B.; Paar, V.; Thieme, M.; Betge, S.; Franz, M.; Hoppe, U.; Lauten, A.; Kammler, J.; et al. Analysis of novel cardiovascular biomarkers in patients with peripheral artery disease. Minerva Med. 2018, 109, 443–450.
6. Bhatt, D.L.; Steg, P.G.; Ohman, E.M.; Hirsch, A.T.; Ikeda, Y.; Mas, J.-L.; Goto, S.; Liau, C.-S.; Richard, A.J.; Röther, J.; et al. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients with Atherothrombosis. JAMA 2006, 295, 180–189.
7. Norgren, L.; Hiatt, W.; Dormandy, J.; Nehler, M.; Harris, K.; Fowkes, F. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J. Vasc. Surg. 2007, 45, S5–S67.
8. Zheng, Z.-J.; Sharrett, A.; Chambless, L.E.; Rosamond, W.D.; Nieto, F.; Sheps, D.S.; Dobs, A.; Evans, G.W.; Heiss, G. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 1997, 131, 115–125.
9. Amrock, S.M.; Weitzman, M. Multiple biomarkers for mortality prediction in peripheral arterial disease. Vasc. Med. 2016, 21, 105–112.
10. Tzoulaki, I.; Murray, G.D.; Lee, A.J.; Rumley, A.; Lowe, G.D.; Fowkes, F.G.R. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur. Hear. J. 2007, 28, 354–362.
11. Ridker, P.; Stampfer, M.; Rifai, N. Novel risk factors for systemic atherosclerosis. A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. ACC Curr. J. Rev. 2001, 10, 25–26.
12. Saenz-Pipaon, G.; San Martín, P.; Planell, N.; Maillo, A.; Ravassa, S.; Vilas-Zornoza, A.; Martinez-Aguilar, E.; Rodriguez, J.A.; Alameda, D.; Lara-Astiaso, D.; et al. Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD). J. Extracell. Vesicles 2020, 9, 1729646.
13. Ding, N.; Yang, C.; Ballew, S.H.; Kalbaugh, C.A.; McEvoy, J.W.; Salameh, M.; Aguilar, D.; Hoogeveen, R.C.; Nambi, V.; Selvin, E.; et al. Fibrosis and Inflammatory Markers and Long-Term Risk of Peripheral Artery Disease. Arter. Thromb. Vasc. Biol. 2020, 40, 2322–2331.
14. Valkova, M.; Lazurova, I.; Petrasova, D.; Frankovicova, M.; Dravecka, I. Humoral predictors of ankle-brachial index in patients with peripheral arterial disease and controls. Bratisl. Med J. 2018, 119, 646–650.
15. Pande, R.L.; Brown, J.; Buck, S.; Redline, W.; Doyle, J.; Plutzky, J.; Creager, M.A. Association of monocyte tumor necrosis factor α expression and serum inflammatory biomarkers with walking impairment in peripheral artery disease. J. Vasc. Surg. 2015, 61, 155–161.
16. Beckman, J.A.; Preis, O.; Ridker, P.M.; Gerhard-Herman, M. Comparison of Usefulness of Inflammatory Markers in Patients with Versus Without Peripheral Arterial Disease in Predicting Adverse Cardiovascular Outcomes (Myocardial Infarction, Stroke, and Death). Am. J. Cardiol. 2005, 96, 1374–1378.
17. Engelberger, R.P.; Limacher, A.; Kucher, N.; Baumann, F.; Silbernagel, G.; Benghozi, R.; Do, D.-D.; Willenberg, T.A.; Baumgartner, I. Biological variation of established and novel biomarkers for atherosclerosis: Results from a prospective, parallel-group cohort study. Clin. Chim. Acta 2015, 447, 16–22.
18. Urbonaviciene, G.; Frystyk, J.; Flyvbjerg, A.; Urbonavicius, S.; Henneberg, E.W.; Lindholt, J.S. Markers of inflammation in relation to long-term cardiovascular mortality in patients with lower-extremity peripheral arterial disease. Int. J. Cardiol. 2012, 160, 89–94.
19. Murabito, J.M.; Keyes, M.J.; Guo, C.-Y.; Keaney, J.F.; Vasan, R.S.; D’Agostino, R.B.; Benjamin, E.J. Cross-sectional relations of multiple inflammatory biomarkers to peripheral arterial disease: The Framingham Offspring Study. Atherosclerosis 2009, 203, 509–514.
20. Tzoulaki, I.; Murray, G.D.; Lee, A.J.; Rumley, A.; Lowe, G.D.; Fowkes, F.G.R. C-Reactive Protein, Interleukin-6, and Soluble Adhesion Molecules as Predictors of Progressive Peripheral Atherosclerosis in the General Population. Circulation 2005, 112, 976–983.
21. Akkoca, M. The Role of Microcirculatory Function and plasma biomarkers in determining the development of cardiovascular adverse events in patients with peripheral arterial disease: A 5 year follow up. Anatol. J. Cardiol. 2018, 20, 220–228.
22. Criqui, M.H.; Ho, L.A.; Denenberg, J.O.; Ridker, P.M.; Wassel, C.L.; McDermott, M.M. Biomarkers in peripheral arterial disease patients and near- and longer-term mortality. J. Vasc. Surg. 2010, 52, 85–90.
23. Vidula, H.; Tian, L.; Liu, K.; Criqui, M.H.; Ferrucci, L.; Pearce, W.H.; Greenland, P.; Green, D.; Tan, J.; Garside, D.B.; et al. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: A cohort study. Ann. Intern. Med. 2008, 148, 85–93.
24. Singh, T.; Morris, D.; Smith, S.; Moxon, J.; Golledge, J. Systematic Review and Meta-Analysis of the Association Between C-Reactive Protein and Major Cardiovascular Events in Patients with Peripheral Artery Disease. Eur. J. Vasc. Endovasc. Surg. 2017, 54, 220–233.
25. Kremers, B.; Wübbeke, L.; Mees, B.; Ten Cate, H.; Spronk, H.; Ten Cate-Hoek, A. Plasma Biomarkers to Predict Cardiovascular Outcome in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis. Arterioscler. Thromb. Vasc. Biol. 2020, 40, 2018–2032.
26. Unlu, Y.; Karapolat, S.; Karaca, Y.; Kiziltunc, A.; Kızıltunç, A. Comparison of levels of inflammatory markers and hemostatic factors in the patients with and without peripheral arterial disease. Thromb. Res. 2006, 117, 357–364.
27. Guo, S.; Zhang, Z.; Wang, L.; Yuan, L.; Bao, J.; Zhou, J.; Jing, Z. Six-month results of stenting of the femoropopliteal artery and predictive value of interleukin-6: Comparison with high-sensitivity C-reactive protein. Vascular 2020, 28, 715–721.
28. Signorelli, S.S.; Mazzarino, M.C.; Di Pino, L.; Malaponte, G.; Porto, C.; Pennisi, G.; Marchese, G.; Costa, M.P.; DiGrandi, D.; Celotta, G.; et al. High circulating levels of cytokines (IL-6 and TNFa), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after a treadmill test. Vasc. Med. 2003, 8, 15–19.
29. Signorelli, S.S.; Anzaldi, M.; Libra, M.; Navolanic, P.M.; Malaponte, G.; Mangano, K.; Quattrocchi, C.; Di Marco, R.; Fiore, V.; Neri, S. Plasma Levels of Inflammatory Biomarkers in Peripheral Arterial Disease. Angiology 2016, 67, 870–874.
30. McDermott, M.M.; Liu, K.; Ferrucci, L.; Tian, L.; Guralnik, J.M.; Green, D.; Tan, J.; Liao, Y.; Pearce, W.H.; Schneider, J.R.; et al. Circulating Blood Markers and Functional Impairment in Peripheral Arterial Disease. J. Am. Geriatr. Soc. 2008, 56, 1504–1510.
31. Russell, K.S.; Yates, D.P.; Kramer, C.M.; Feller, A.; Mahling, P.; Colin, L.; Clough, T.; Wang, T.; LaPerna, L.; Patel, A.; et al. A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease. Vasc. Med. 2019, 24, 414–421.
32. Edlinger, C.; Lichtenauer, M.; Wernly, B.; Pistulli, R.; Paar, V.; Prodinger, C.; Krizanic, F.; Thieme, M.; Kammler, J.; Jung, C.; et al. Disease-specific characteristics of vascular cell adhesion molecule-1 levels in patients with peripheral artery disease. Heart Vessel. 2019, 34, 976–983.
33. Zamzam, A.; Syed, M.H.; Rand, M.L.; Singh, K.; A Hussain, M.; Jain, S.; Khan, H.; Verma, S.; Al-Omran, M.; Abdin, R.; et al. Altered coagulation profile in peripheral artery disease patients. Vascular 2020, 28, 368–377.
34. Altes, P.; Perez, P.; Esteban, C.; Muñoz-Torrero, J.F.S.; Aguilar, E.; García-Díaz, A.M.; Álvarez, L.R.; Jiménez, P.E.; Sahuquillo, J.C.; Monreal, M.; et al. Raised Fibrinogen Levels and Outcome in Outpatients with Peripheral Artery Disease. Angiology 2018, 69, 507–512.
35. Bartlett, J.W.; De Stavola, B.L.; Meade, T.W. Assessing the contribution of fibrinogen in predicting risk of death in men with peripheral arterial disease. J. Thromb. Haemost. 2009, 7, 270–276.
36. Doweik, L.; Maca, T.; Schillinger, M.; Budinsky, A.; Sabeti, S.; Minar, E. Fibrinogen Predicts Mortality in High Risk Patients with Peripheral Artery Disease. Eur. J. Vasc. Endovasc. Surg. 2003, 26, 381–386.
37. McDermott, M.M.; Liu, K.; Green, D.; Greenland, P.; Tian, L.; Kibbe, M.; Tracy, R.; Shah, S.; Wilkins, J.T.; Huffman, M.; et al. Changes in D-dimer and inflammatory biomarkers before ischemic events in patients with peripheral artery disease: The BRAVO Study. Vasc. Med. 2015, 21, 12–20.
38. Teperman, J.; Carruthers, D.; Guo, Y.; Barnett, M.P.; Harris, A.A.; Sedlis, S.P.; Pillinger, M.; Babaev, A.; Staniloae, C.; Attubato, M.; et al. Relationship between neutrophil-lymphocyte ratio and severity of lower extremity peripheral artery disease. Int. J. Cardiol. 2017, 228, 201–204.
39. Selvaggio, S.; Abate, A.; Brugaletta, G.; Musso, C.; Di Guardo, M.; Di Guardo, C.; Vicari, E.S.D.; Romano, M.; Luca, S.; Signorelli, S.S. Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio and monocyte-to-HDL cholesterol ratio as markers of peripheral artery disease in elderly patients. Int. J. Mol. Med. 2020, 46, 1210–1216.
40. Celebi, S.; Berkalp, B.; Amasyali, B. The association between thrombotic and inflammatory biomarkers and lower-extremity peripheral artery disease. Int. Wound J. 2020, 17, 1346–1355.
41. Luo, H.; Yuan, D.; Yang, H.; Yukui, M.; Huang, B.; Yang, Y.; Xiong, F.; Zeng, G.; Wu, Z.; Chen, X.; et al. Post-treatment neutrophil-lymphocyte ratio independently predicts amputation in critical limb ischemia without operation. Clinics 2015, 70, 273–277.
42. Erturk, M.; Cakmak, H.A.; Surgit, O.; Celik, O.; Aksu, H.U.; Akgul, O.; Gurdogan, M.; Bulut, U.; Ozalp, B.; Akbay, E.; et al. The predictive value of elevated neutrophil to lymphocyte ratio for long-term cardiovascular mortality in peripheral arterial occlusive disease. J. Cardiol. 2014, 64, 371–376.
43. Lee, S.; Hoberstorfer, T.; Wadowski, P.P.; Kopp, C.W.; Panzer, S.; Gremmel, T. Platelet-to-lymphocyte and Neutrophil-to-lymphocyte Ratios Predict Target Vessel Restenosis after Infrainguinal Angioplasty with Stent Implantation. J. Clin. Med. 2020, 9, 1729.
44. González-Fajardo, J.A.; Brizuela-Sanz, J.A.; Aguirre-Gervás, B.; Merino-Díaz, B.; Del Río-Solá, L.; Martín-Pedrosa, M.; Vaquero-Puerta, C. Prognostic Significance of an Elevated Neutrophil–Lymphocyte Ratio in the Amputation-free Survival of Patients with Chronic Critical Limb Ischemia. Ann. Vasc. Surg. 2014, 28, 999–1004.
45. Pourafkari, L.; Choi, C.; Garajehdaghi, R.; Tajlil, A.; Dosluoglu, H.H.; Nader, N.D. Neutrophil–lymphocyte ratio is a marker of survival and cardiac complications rather than patency following revascularization of lower extremities. Vasc. Med. 2018, 23, 437–444.
46. Chan, C.; Puckridge, P.; Ullah, S.; Delaney, C.; Spark, J.I. Neutrophil-lymphocyte ratio as a prognostic marker of outcome in infrapopliteal percutaneous interventions for critical limb ischemia. J. Vasc. Surg. 2014, 60, 661–668.
47. Igari, K.; Kudo, T.; Toyofuku, T.; Inoue, Y. Relationship of Inflammatory Biomarkers with Severity of Peripheral Arterial Disease. Int. J. Vasc. Med. 2016, 2016, 1–6.
48. Ueki, Y.; Miura, T.; Miyashita, Y.; Ebisawa, S.; Motoki, H.; Izawa, A.; Koyama, J.; Ikeda, U. Inflammatory Cytokine Levels After Endovascular Therapy in Patients with Peripheral Artery Disease. Angiology 2017, 68, 734–740.
49. Bath, J.; Smith, J.B.; Kruse, R.L.; Vogel, T.R. Neutrophil-lymphocyte ratio predicts disease severity and outcome after lower extremity procedures. J. Vasc. Surg. 2020, 72, 622–631.
50. Paquissi, F.C. The role of inflammation in cardiovascular diseases: The predictive value of neutrophil–lymphocyte ratio as a marker in peripheral arterial disease. Ther. Clin. Risk Manag. 2016, 12, 851–860.
51. Fowkes, F.G.R.; Aboyans, V.; McDermott, M.M.; Sampson, U.K.A.; Criqui, M.H. Peripheral artery disease: Epidemiology and global perspectives. Nat. Rev. Cardiol. 2017, 14, 156–170.
52. Egnot, N.S.; Barinas-Mitchell, E.; Criqui, M.H.; Allison, M.A.; Ix, J.H.; Jenny, N.S.; Wassel, C.L. An exploratory factor analysis of inflammatory and coagulation markers associated with femoral artery atherosclerosis in the San Diego Population Study. Thromb. Res. 2018, 164, 9–14.
53. Signorelli, S.S.; Anzaldi, M.; Fiore, V.; Simili, M.; Puccia, G.; Libra, M.; Malaponte, G.; Neri, S. Patients with unrecognized peripheral arterial disease (PAD) assessed by ankle-brachial index (ABI) present a defined profile of proinflammatory markers compared to healthy subjects. Cytokine 2012, 59, 294–298.
54. Bayoglu, B.; Arslan, C.; Tel, C.; Ulutin, T.; Dirican, A.; Deser, S.B.; Cengiz, M. Genetic variants rs1994016 and rs3825807 in ADAMTS7 affect its mRNA expression in atherosclerotic occlusive peripheral arterial disease. J. Clin. Lab. Anal. 2018, 32, e22174.
55. Martínez-Aguilar, E.; Gomez-Rodriguez, V.; Orbe, J.; Rodríguez, J.A.; Fernández-Alonso, L.; Roncal, C.; Paramo, J.A. Matrix metalloproteinase 10 is associated with disease severity and mortality in patients with peripheral arterial disease. J. Vasc. Surg. 2015, 61, 428–435.
56. Tayebjee, M.H.; Tan, K.T.; MacFadyen, R.J.; Lip, G.Y.H. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: Relationship to disease severity. J. Intern. Med. 2004, 257, 110–116.
57. Baum, O.; Ganster, M.; Baumgartner, I.; Nieselt, K.; Djonov, V. Basement Membrane Remodeling in Skeletal Muscles of Patients with Limb Ischemia Involves Regulation of Matrix Metalloproteinases and Tissue Inhibitor of Matrix Metalloproteinases. J. Vasc. Res. 2007, 44, 202–213.
58. E Muhs, B.; Plitas, G.; Delgado, Y.; Ianus, I.; Shaw, J.P.; Adelman, M.A.; Lamparello, P.; Shamamian, P.; Gagne, P. Temporal expression and activation of matrix metalloproteinases-2, -9, and membrane type 1-matrix metalloproteinase following acute hindlimb ischemia. J. Surg. Res. 2003, 111, 8–15.
59. Muhs, B.E.; Gagne, P.; Plitas, G.; Shaw, J.P.; Shamamian, P. Experimental hindlimb ischemia leads to neutrophil-mediated increases in gastrocnemius MMP-2 and -9 activity: A potential mechanism for ischemia induced MMP activation. J. Surg. Res. 2004, 117, 249–254.
60. Gomez-Rodriguez, V.; Orbe, J.; Martinez-Aguilar, E.; Rodriguez, J.A.; Fernandez-Alonso, L.; Serneels, J.; Bobadilla, M.; Perez-Ruiz, A.; Collantes, M.; Mazzone, M.; et al. Functional MMP-10 is required for efficient tissue repair after experimental hind limb ischemia. FASEB J. 2014, 29, 960–972.
61. Meisner, J.K.; Annex, B.H.; Price, R.J. Despite normal arteriogenic and angiogenic responses, hind limb perfusion recovery and necrotic and fibroadipose tissue clearance are impaired in matrix metalloproteinase 9-deficient mice. J. Vasc. Surg. 2015, 61, 1583–1594.
62. Johnson, C.; Sung, H.J.; Lessner, S.M.; Fini, M.E.; Galis, Z.S. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: Potential role in capillary branching. Circ. Res. 2004, 94, 262–268.
63. Huang, P.-H.; Chen, Y.-H.; Wang, C.-H.; Chen, J.-S.; Tsai, H.-Y.; Lin, F.-Y.; Lo, W.-Y.; Wu, T.-C.; Sata, M.; Chen, J.-W.; et al. Matrix Metalloproteinase-9 Is Essential for Ischemia-Induced Neovascularization by Modulating Bone Marrow–Derived Endothelial Progenitor Cells. Arter. Thromb. Vasc. Biol. 2009, 29, 1179–1184.
64. Morishita, T.; Uzui, H.; Nakano, A.; Mitsuke, Y.; Geshi, T.; Ueda, T.; Lee, J.-D. Number of Endothelial Progenitor Cells in Peripheral Artery Disease as a Marker of Severity and Association with Pentraxin-3, Malondialdehyde-Modified Low-Density Lipoprotein and Membrane Type-1 Matrix Metalloproteinase. J. Atheroscler. Thromb. 2012, 19, 149–158.
65. Vagima, Y.; Avigdor, A.; Goichberg, P.; Shivtiel, S.; Tesio, M.; Kalinkovich, A.; Golan, K.; Dar, A.; Kollet, O.; Petit, I.; et al. MT1-MMP and RECK are involved in human CD34+ progenitor cell retention, egress, and mobilization. J. Clin. Investig. 2009, 119, 492–503.
66. Signorelli, S.S.; Malaponte, G.; Libra, M.; Di Pino, L.; Celotta, G.; Bevelacqua, V.; Petrina, M.; Nicotra, G.S.; Indelicato, M.; Navolanic, P.M.; et al. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc. Med. 2005, 10, 1–6.
67. Chung, A.W.Y.; Hsiang, Y.N.; Matzke, L.A.; McManus, B.M.; Van Breemen, C.; Okon, E.B. Reduced Expression of Vascular Endothelial Growth Factor Paralleled with the Increased Angiostatin Expression Resulting from the Upregulated Activities of Matrix Metalloproteinase-2 and -9 in Human Type 2 Diabetic Arterial Vasculature. Circ. Res. 2006, 99, 140–148.
68. Preil, S.A.R.; Thorsen, A.-S.F.; Christiansen, A.L.; Poulsen, M.K.; Karsdal, M.A.; Leeming, D.J.; Rasmussen, L.M. Is cardiovascular disease in patients with diabetes associated with serum levels of MMP-2, LOX, and the elastin degradation products ELM and ELM-2? Scand. J. Clin. Lab. Investig. 2017, 77, 493–497.
69. Ward, M.R.; Pasterkamp, G.; Yeung, A.C.; Borst, C. Arterial remodeling: Mechanisms and clinical implications. Circulation 2000, 102, 1186–1191.
70. Yahagi, K.; Otsuka, F.; Sakakura, K.; Sanchez, O.D.; Kutys, R.; Ladich, E.; Kolodgie, F.D.; Virmani, R.; Joner, M. Pathophysiology of superficial femoral artery in-stent restenosis. J. Cardiovasc. Surg. 2014, 55, 307–323.
71. Giagtzidis, I.T.; Kadoglou, N.P.; Mantas, G.; Spathis, A.; Papazoglou, K.O.; Karakitsos, P.; Liapis, C.D.; Karkos, C.D. The Profile of Circulating Matrix Metalloproteinases in Patients Undergoing Lower Limb Endovascular Interventions for Peripheral Arterial Disease. Ann. Vasc. Surg. 2017, 43, 188–196.
72. Caruana, L.; Formosa, C.; Cassar, K. Prediction of wound healing after minor amputations of the diabetic foot. J. Diabetes Complicat. 2015, 29, 834–837.
73. Becker, F.; Robert-Ebadi, H.; Ricco, J.-B.; Setacci, C.; Cao, P.; de Donato, G.; Eckstein, H.; De Rango, P.; Diehm, N.; Schmidli, J.; et al. Chapter I: Definitions, Epidemiology, Clinical Presentation and Prognosis. Eur. J. Vasc. Endovasc. Surg. 2011, 42, S4–S12.
74. Criqui, M.H.; Aboyans, V. Epidemiology of Peripheral Artery Disease. Circ. Res. 2015, 116, 1509–1526.
75. Sapienza, P.; Di Marzo, L.; Borrelli, V.; Sterpetti, A.; Mingoli, A.; Piagnerelli, R.; Cavallaro, A. Basic Fibroblast Growth Factor Mediates Carotid Plaque Instability Through Metalloproteinase-2 and -9 Expression. Eur. J. Vasc. Endovasc. Surg. 2004, 28, 89–97.
76. Sapienza, P.; Mingoli, A.; Borrelli, V.; Brachini, G.; Biacchi, D.; Sterpetti, A.V.; Grande, R.; Serra, R.; Tartaglia, E. Inflammatory biomarkers, vascular procedures of lower limbs, and wound healing. Int. Wound J. 2019, 16, 716–723.
77. Matsushita, K.; Kwak, L.; Yang, C.; Pang, Y.; Ballew, S.H.; Sang, Y.; Hoogeveen, R.C.; Jaar, B.G.; Selvin, E.; Ballantyne, C.M.; et al. High-sensitivity cardiac troponin and natriuretic peptide with risk of lower-extremity peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) Study. Eur. Hear. J. 2018, 39, 2412–2419.
78. Fatemi, S.; Acosta, S.; Gottsäter, A.; Melander, O.; Engström, G.; Dakhel, A.; Zarrouk, M. Copeptin, B-type natriuretic peptide and cystatin C are associated with incident symptomatic PAD. Biomarkers 2019, 24, 615–621.
79. Ye, Z.; Ali, Z.; Klee, G.G.; Mosley, T.H.; Kullo, I.J. Associations of Candidate Biomarkers of Vascular Disease with the Ankle-Brachial Index and Peripheral Arterial Disease. Am. J. Hypertens. 2013, 26, 495–502.
80. Pohlhammer, J.; Kronenberg, F.; Rantner, B.; Stadler, M.; Peric, S.; Hammerer-Lercher, A.; Klein-Weigel, P.; Fraedrich, G.; Kollerits, B. High-sensitivity cardiac troponin T in patients with intermittent claudication and its relation with cardiovascular events and all-cause mortality—The CAVASIC Study. Atherosclerosis 2014, 237, 711–717.
81. Janus, S.E.; Hajjari, J.; Al-Kindi, S.G. High Sensitivity Troponin and Risk of Incident Peripheral Arterial Disease in Chronic Kidney Disease (from the Chronic Renal Insufficiency Cohort [CRIC] Study). Am. J. Cardiol. 2020, 125, 630–635.
82. Shigeta, T.; Kimura, S.; Takahashi, A.; Isobe, M.; Hikita, H. Coronary Artery Disease Severity and Cardiovascular Biomarkers in Patients with Peripheral Artery Disease. Int. J. Angiol. 2015, 24, 278–282.
83. Mueller, T.; Dieplinger, B.; Poelz, W.; Endler, G.; Wagner, O.F.; Haltmayer, M. Amino-Terminal Pro–B-Type Natriuretic Peptide as Predictor of Mortality in Patients with Symptomatic Peripheral Arterial Disease: 5-Year Follow-Up Data from the Linz Peripheral Arterial Disease Study. Clin. Chem. 2009, 55, 68–77.
84. Mueller, T.; Hinterreiter, F.; Luft, C.; Poelz, W.; Haltmayer, M.; Dieplinger, B. Mortality rates and mortality predictors in patients with symptomatic peripheral artery disease stratified according to age and diabetes. J. Vasc. Surg. 2014, 59, 1291–1299.
85. Skoglund, P.H.; Arpegård, J.; Östergren, J.; Svensson, P. Amino-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein but Not Cystatin C Predict Cardiovascular Events in Male Patients with Peripheral Artery Disease Independently of Ambulatory Pulse Pressure. Am. J. Hypertens. 2014, 27, 363–371.
86. Falkensammer, J.; Frech, A.; Duschek, N.; Gasteiger, S.; Stojakovic, T.; Scharnagl, H.; Huber, K.; Fraedrich, G.; Greiner, A. Prognostic relevance of ischemia-modified albumin and NT-proBNP in patients with peripheral arterial occlusive disease. Clin. Chim. Acta 2015, 438, 255–260.
87. Clemens, R.K.; Annema, W.; Baumann, F.; Roth-Zetzsche, S.; Seifert, B.; Von Eckardstein, A.; Amann-Vesti, B.R.; Roth-Zetsche, S. Cardiac biomarkers but not measures of vascular atherosclerosis predict mortality in patients with peripheral artery disease. Clin. Chim. Acta 2019, 495, 215–220.
88. Linnemann, B.; Sutter, T.; Herrmann, E.; Sixt, S.; Rastan, A.; Schwarzwaelder, U.; Noory, E.; Buergelin, K.; Beschorner, U.; Zeller, T. Elevated Cardiac Troponin T Is Associated with Higher Mortality and Amputation Rates in Patients with Peripheral Arterial Disease. J. Am. Coll. Cardiol. 2014, 63, 1529–1538.
89. Linnemann, B.; Sutter, T.; Sixt, S.; Rastan, A.; Schwarzwaelder, U.; Noory, E.; Buergelin, K.; Beschorner, U.; Zeller, T. Elevated cardiac troponin T contributes to prediction of worse in-hospital outcomes after endovascular therapy for acute limb ischemia. J. Vasc. Surg. 2012, 55, 721–729.
90. Szczeklik, W.; Krzanowski, M.; Maga, P.; Partyka, Ł.; Kościelniak, J.; Kaczmarczyk, P.; Maga, M.; Pieczka, P.; Suska, A.; Wachsmann, A.; et al. Myocardial injury after endovascular revascularization in critical limb ischemia predicts 1-year mortality: A prospective observational cohort study. Clin. Res. Cardiol. 2017, 107, 319–328.
91. Stone, P.A.; Schlarb, H.; Campbell, J.E.; Williams, D.; Thompson, S.N.; John, M.; Campbell, J.R.; AbuRahma, A.F. C-reactive protein and brain natriuretic peptide as predictors of adverse events after lower extremity endovascular revascularization. J. Vasc. Surg. 2014, 60, 652–660.
92. Dickhout, A.; Koenen, R.R. Extracellular Vesicles as Biomarkers in Cardiovascular Disease; Chances and Risks. Front. Cardiovasc. Med. 2018, 5, 113.
93. Riancho, J.; Sánchez-Juan, P. Circulating Extracellular Vesicles in Human Disease. N. Engl. J. Med. 2018, 379, 2179–2181.
94. Théry, C.; Witwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Anderson, J.D.; Andriantsitohaina, R.; Antoniou, A.; Arab, T.; Archer, F.; Atkin-Smith, G.K.; et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 2018, 7, 1535750.
95. Jansen, F.; Nickenig, G.; Werner, N. Extracellular Vesicles in Cardiovascular Disease. Circ. Res. 2017, 120, 1649–1657.
96. Zarà, M.; Guidetti, G.F.; Camera, M.; Canobbio, I.; Amadio, P.; Torti, M.; Tremoli, E.; Barbieri, S.S. Biology and Role of Extracellular Vesicles (EVs) in the Pathogenesis of Thrombosis. Int. J. Mol. Sci. 2019, 20, 2840.
97. Zeiger, F.; Stephan, S.; Hoheisel, G.; Pfeiffer, D.; Ruehlmann, C.; Koksch, M. P-Selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease. Blood Coagul. Fibrinolysis 2000, 11, 723–728.
98. Tan, K.T.; Tayebjee, M.H.; Lynd, C.; Blann, A.D.; Lip, G.Y.H. Platelet microparticles and soluble P selectin in peripheral artery disease: Relationship to extent of disease and platelet activation markers. Ann. Med. 2005, 37, 61–66.
99. Van Der Zee, P.M.; Biró, É.; Ko, Y.; De Winter, R.J.; Hack, C.E.; Sturk, A.; Nieuwland, R. P-Selectin- and CD63-Exposing Platelet Microparticles Reflect Platelet Activation in Peripheral Arterial Disease and Myocardial Infarction. Clin. Chem. 2006, 52, 657–664.
100. Hiatt, W.R.; Armstrong, E.J.; Larson, C.J.; Brass, E.P. Pathogenesis of the Limb Manifestations and Exercise Limitations in Peripheral Artery Disease. Circ. Res. 2015, 116, 1527–1539.
101. Li, P.; Qin, C. Elevated Circulating VE-Cadherin+CD144+Endothelial Microparticles in Ischemic Cerebrovascular Disease. Thromb. Res. 2015, 135, 375–381.
102. Koga, H.; Sugiyama, S.; Kugiyama, K.; Watanabe, K.; Fukushima, H.; Tanaka, T.; Sakamoto, T.; Yoshimura, M.; Jinnouchi, H.; Ogawa, H. Elevated Levels of VE-Cadherin-Positive Endothelial Microparticles in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease. J. Am. Coll. Cardiol. 2005, 45, 1622–1630.
103. Amabile, N.; Guérin, A.P.; Leroyer, A.; Mallat, Z.; Nguyen, C.; Boddaert, J.; London, G.M.; Tedgui, A.; Boulanger, C.M. Circulating Endothelial Microparticles Are Associated with Vascular Dysfunction in Patients with End-Stage Renal Failure. J. Am. Soc. Nephrol. 2005, 16, 3381–3388.
104. Werner, N.; Wassmann, S.; Ahlers, P.; Kosiol, S.; Nickenig, G. Circulating CD31+/Annexin V+Apoptotic Microparticles Correlate with Coronary Endothelial Function in Patients with Coronary Artery Disease. Arter. Thromb. Vasc. Biol. 2006, 26, 112–116.
105. Schiro, A.; Wilkinson, F.L.; Weston, R.; Smyth, J.V.; Serracino-Inglott, F.; Alexander, M.Y. Elevated levels of endothelial-derived microparticles and serum CXCL9 and SCGF-β are associated with unstable asymptomatic carotid plaques. Sci. Rep. 2015, 5, 16658.
106. Wekesa, A.; Cross, K.; O’Donovan, O.; Dowdall, J.; O’Brien, O.; Doyle, M.; Byrne, L.; Phelan, J.; Ross, M.; Landers, R.; et al. Predicting Carotid Artery Disease and Plaque Instability from Cell-derived Microparticles. Eur. J. Vasc. Endovasc. Surg. 2014, 48, 489–495.
107. Crawford, J.R.; Trial, J.; Nambi, V.; Hoogeveen, R.C.; Taffet, G.E.; Entman, M.L. Plasma Levels of Endothelial Microparticles Bearing Monomeric C-reactive Protein are Increased in Peripheral Artery Disease. J. Cardiovasc. Transl. Res. 2016, 9, 184–193.
108. Giarretta, I.; Gatto, I.; Marcantoni, M.; Lupi, G.; Tonello, D.; Gaetani, E.; Pitocco, D.; Iezzi, R.; Truma, A.; Porfidia, A.; et al. Microparticles Carrying Sonic Hedgehog Are Increased in Humans with Peripheral Artery Disease. Int. J. Mol. Sci. 2018, 19, 3954.
109. Leroyer, A.S.; Ebrahimian, T.G.; Cochain, C.; Récalde, A.; Blanc-Brude, O.; Mees, B.; Vilar, J.; Tedgui, A.; Levy, B.I.; Chimini, G.; et al. Microparticles from ischemic muscle promotes postnatal vasculogenesis. Circulation 2009, 119, 2808–2817.
110. Sorrentino, T.A.; Duong, P.; Bouchareychas, L.; Chen, M.; Chung, A.; Schaller, M.S.; Oskowitz, A.; Raffai, R.L.; Conte, M.S. Circulating exosomes from patients with peripheral artery disease influence vascular cell migration and contain distinct microRNA cargo. JVS Vasc. Sci. 2020, 1, 28–41.
111. Chitoiu, L.; Dobranici, A.; Gherghiceanu, M.; Dinescu, S.; Costache, M. Multi-Omics Data Integration in Extracellular Vesicle Biology—Utopia or Future Reality? Int. J. Mol. Sci. 2020, 21, 8550.
112. Rosińska, J.; Łukasik, M.; Kozubski, W. The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles. Cardiovasc. Drugs Ther. 2017, 31, 627–644.
113. Nomura, S.; Inami, N.; Iwasaka, T.; Liu, Y. Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: Therapeutic effects by cilostazol and potentiation by dipyridamole. Platelets 2004, 15, 167–172.
114. Mobarrez, F.; He, S.; Bröijersen, A.; Wiklund, B.; Antovic, A.; Antovic, J.; Egberg, N.; Jörneskog, G.; Wallén, H. Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. Thromb. Haemost. 2011, 106, 344–352.
115. Mobarrez, F.; Egberg, N.; Antovic, J.; Bröijersen, A.; Jörneskog, G.; Wallén, H. Release of endothelial microparticles in vivo during atorvastatin treatment; a randomized double-blind placebo-controlled study. Thromb. Res. 2012, 129, 95–97.